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Biology is all about turning things on
and off. Pharmaceuticals are part of
that same picture: most protein drugs
turn on or block a receptor, and most
small molecule drugs turn off a
protein target. Each of those
recognition events is unique,
because the binding surface on each
protein is unique. 
Sangamo BioSciences, Inc.
(Richmond, California) thinks it has
found a more streamlined, rational
approach to this problem. Sangamo’s
target is DNA, which shows enough
variation to allow selective targeting,
but enough consistency to allow the
use of a single framework for
thousands of different activators and
inhibitors. Within that framework —
the family of zinc finger transcription
factors — Sangamo is inventing a
new genetic code. They hope that
the code will allow them to rationally
target any site in the genome and
thus turn on or off any gene. 
A transcription factor from Legoland 
Edward Lanphier became the
founder and CEO of Sangamo in
1995. By then he had seen the inside
of several pharmaceutical and
biotechnology companies, and had
experienced the difficulties of
developing gene therapy firsthand. 
Lanphier was discussing gene
therapy strategy at Johns Hopkins
University (Baltimore, Maryland)
when he came across a whole new
world of opportunity: zinc finger
proteins (ZFPs). “There were a lot of
people [in gene therapy] working on
vectors and not many people
thinking about what they would
deliver once it did work,” says
Jeremy Berg of Johns Hopkins, who
is now on the Sangamo scientific
advisory board. ZFPs looked like a
good bet. This was based on the
structure of the protein bound to
DNA, which was solved first by Carl
Pabo (Massachusetts Institute of
Technology, Cambridge,
Massachusetts) for Zif268, a mouse
zinc finger transcription factor. 
Each of the three zinc fingers of
Zif268 recognizes a three-base
subsite in the nine-base binding site.
The 30-amino-acid zinc-finger is too
small to fold by itself, but is glued
together by a coordinating zinc atom.
An α-helix from each finger lies in
the DNA major groove and contacts
three contiguous bases, with each
finger interacting with the DNA
independently. This modularity
contrasts with the unpredictability of
the many transcription factors that
bind as dimers. Dimeric proteins
require palindromic recognition sites
and are sensitive to poorly
understood quaternary interactions.
Sangamo develops custom-
designed switches for any gene.
“What became clear is that zinc
fingers are the only class of
transcription factor that binds in this
repeated and rational manner to
DNA, and therefore the only
transcription factor that is amenable
to rational design,” says Lanphier.
“Over the years that has proven to be
true.” According to Berg, “they’re a
natural for mixing and matching.”
Deciphering the code
Once the structure was in,
researchers like Berg, Pabo, Aaron
Klug (Medical Research Council,
Cambridge, UK) and Carlos Barbas
(Scripps Research Institute, La Jolla,
California) focused on the
relationship between protein and
DNA sequences. Could they come
up with a one-to-one relationship, so
that 64 interchangeable fingers could
be designed for the 64 possible
3-base subsites?
The important contacts to DNA
bases are made by three amino acids
in each α-helix. Inspection of
known ZFPs and structures
suggested that some elements of a
code existed, but far more
information came from phage
display experiments. Pabo, Klug,
Barbas and a group from Genentech
(South San Francisco, California)
expressed libraries of mutated zinc
fingers on the surface of phage, and
tested them for their binding to
DNA. Sadly, the modularity of each
zinc finger was incomplete. 
Pabo’s response was to evolve
each finger in sequence, so that it
was selected in the context of its
newly modified neighbor. This gave
a jump in affinity, and provided
invaluable information about the
types of influences of one finger on
the binding of a neighboring finger,
but it was not practical for a company
hoping for an efficient production
line. Sangamo did not have the time
or resources to create and screen
three sequential phage libraries for
each new DNA sequence. The
problem only increased when Barbas
introduced six-finger proteins to
increase affinity (Figure 1).
Sangamo could, of course, simply
ignore the inter-finger contacts. “To
a first approximation I think pasting
things together works,” says Berg,
“but then there are also more
sophisticated additions that you can
make.” Zif268, for example, has just
one key inter-finger contact — from
an aspartate to the complementary
cytosine in each preceding GNN
subsite. Barbas has included this
contact in his set of 16 fingers that he
has selected for binding to GNN
subsites. The result is a set of fingers
that are fully modular in the context
of the nearly 17 million possible
(GNN)6 sequences. 
Sangamo has been expanding on
such approaches and learning from
each of its contract jobs. Lanphier
says that constructing a new protein
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“is not automatic, but Sangamo has
built an empirically derived
database that we draw on for every
target, so it’s far from starting at
ground zero. We’re not at the point
where we sit down at the computer,
put in the sequence and, bang, we
have a protein, but we’re moving in
that direction.”
Hold me tight (but not too tight)
One of the unresolved questions in
zinc finger design is just how much
affinity is desirable. Less can be
more. Barbas used site-directed
mutagenesis to improve the
specificity (or discrimination) of his
GNN set, and found that it was the
proteins with the lowest affinities
that had the best specificities.
Natural transcription factors bind a
family of closely related sites, and it
may be unreasonable to expect
complete specificity from a
designed protein. “If you listen to
the PR and say you can regulate one
site in the genome I think that’s
incredibly naive and probably
irrelevant,” says Berg. “If you bind
with reasonable affinity you will
almost certainly bind other sites
with some affinity and you won’t be
approaching equilibrium.” 
The study of six-finger proteins
has yielded clues. They show
modest increases in in vitro affinity
compared to three-finger proteins,
but their biological effectiveness is
far greater. Perhaps the increased
affinity, by lengthening the time
spent binding to DNA, makes the
difference between a protein that
works and a protein that binds but
falls off before doing its job. Proteins
that are close to this threshold will
work the best in cells.
Go ahead — try it out
Theorizing is all very well, but
affinity and specificity problems are
sufficiently nebulous that the only
true test may be experience. Plus
Sangamo needs cash flow. So far the
company has made deals with 11
partners to supply ZFPs that regulate
a specific number of targets. These
proteins are for use in functional
genomics — determining the
function of a gene by turning it on or
off, either in cells or transgenic
animals. The transcriptional
activation or repression domains
linked to the ZFP can function at a
distance from the transcriptional start
site, so the binding site for the ZFP
can be within the coding sequence.
Thus there is no need to isolate the
promoters corresponding to
expressed sequence tags (ESTs). 
ZFPs are preferable to antisense
because they can turn genes either
on or off, and their target is a linear
molecule, rather than the
extensively folded mRNA. Lanphier
hopes to add small-molecule control
of the ZFPs in the near future, and
he is investigating large-scale
mutation detection with an
unnamed chip company.
Sangamo hopes to hit the clinic in
2001 with ZFPs that turn on the
production of well characterized
proteins such as vascular endothelial
growth factor (VEGF). Patent
infringement should not be a
problem as Sangamo is targeting the
endogenous gene. Gene delivery is
another matter. “N years down the
road, where N is between 2 and 50,
gene delivery will be standard
practice,” says Berg. Lanphier feels
the necessary technology is already
winding its way through clinical
trials, but, at least in the short term,
Berg remains cautious. “In the long
run I think this technology could be
very important for therapeutic
applications,” he says. “It’s the pot of
gold on the horizon.” 
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A protein with six zinc fingers. The structures
are based on the coordinates of the three-
finger protein Zif268, which contacts primarily
one DNA strand (shown here in red). The top
view shows the backbone structure of the
protein with DNA-contacting residues as stick
representations. Each of the six zinc-finger
modules features an α helix, which lies in the
DNA major groove and functions as the
reading head. The helical path of the protein
is emphasized by the lower picture, which
shows only the three amino acid residues
from each finger that contact the DNA. Figure
courtesy of David Segal and Carlos Barbas.
